ESMO 2017: First-line Crizotinib Versus Chemotherapy in ALK-Positive Lung Cancer
Tony Mok, MD, Chair of the Department of Clinical Oncology, Chinese University of Hong Kong, presented the updated overall survival data from the PROFILE 104 trial at the 2017 European Society for Medical Oncology (ESMO) Congress (Abstract LBA50). This is the longest ever follow-up reported for patients with advanced ALK-positive non–small cell lung cancer (NSCLC).
This phase III trial of 343 patients examined the efficacy of the oral ALK inhibitor crizotinib versus chemotherapy in previously untreated patients with ALK-positive advanced NSCLC. After a median follow-up of 46 months, median overall survival for patients randomized to crizotinib has still not been reached and was 47.5 months for patients randomized to chemotherapy.
“PROFILE 1014 has provided important new data for patients with non–small cell lung cancer," said Dr. Mok in a press release. "This is the first set of prospective data from a randomized phase III study to report long-term survival outcomes for patients with ALK-positive non–small cell lung cancer.”
The primary endpoint of PROFILE 1014—progression-free survival—was met and published in 2014 in The New England Journal of Medicine. A statistically significant improvement in progression-free survival was reported in patients treated with crizotinib.